现代肿瘤医学
現代腫瘤醫學
현대종류의학
JOURNAL OF MODERN ONCOLOGY
2010年
5期
1037-1041
,共5页
ERCC1%BRCA1%耐药%肺癌
ERCC1%BRCA1%耐藥%肺癌
ERCC1%BRCA1%내약%폐암
顺铂广泛应用于非小细胞癌(non-small cell lung cancer,NSCIC)的化疗,但耐药性的产生严重影响其疗效.顺铂耐药的机制尚不十分清楚.目前普遍认为错配切除修复蛋白1(excision repair cross completion gene 1,ERCC1)及乳腺癌易感基因1(breast cancer susceptibility gene 1,BRCA1)的表达与顺铂耐药性相关.抑制ERCC1及BRCA1的表达可克服顺铂耐药性,提高治疗效果.
順鉑廣汎應用于非小細胞癌(non-small cell lung cancer,NSCIC)的化療,但耐藥性的產生嚴重影響其療效.順鉑耐藥的機製尚不十分清楚.目前普遍認為錯配切除脩複蛋白1(excision repair cross completion gene 1,ERCC1)及乳腺癌易感基因1(breast cancer susceptibility gene 1,BRCA1)的錶達與順鉑耐藥性相關.抑製ERCC1及BRCA1的錶達可剋服順鉑耐藥性,提高治療效果.
순박엄범응용우비소세포암(non-small cell lung cancer,NSCIC)적화료,단내약성적산생엄중영향기료효.순박내약적궤제상불십분청초.목전보편인위착배절제수복단백1(excision repair cross completion gene 1,ERCC1)급유선암역감기인1(breast cancer susceptibility gene 1,BRCA1)적표체여순박내약성상관.억제ERCC1급BRCA1적표체가극복순박내약성,제고치료효과.
